Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
Toxicity, biodistribution and persistence of candidate HIV vaccines pTHr.HIVA, a recombinant DNA, and MVA.HIVA, a recombinant modified vaccinia virus Ankara, were determined in the Balb/c mouse. The mice were injected with either two doses of intramuscular pTHr.HIVA DNA (50 microg each, separated by an interval of 14 days), two doses of intradermal MVA.HIVA (10(6) plaque-forming units each, separated by an interval of 14 days), or a combination of the two vaccines, each given in two doses, in a prime-boost regimen. The study showed no significant toxic effects, either local or systemic, under any of these employed dosing regimens. With the exception of the sites of delivery, the vaccine-derived HIVA DNA sequences were undetectable 5 weeks after the last dosing. Thus, both the vaccines alone and in a combination were considered safe and suitable for the use in phase I trials in humans.
Hanke
T
T
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, Oxford OX3 9DS, UK. thanke@molbiol.ox.ac.uk
McMichael
A J
AJ
Samuel
Rachel V
RV
Powell
L A J
LA
McLoughlin
L
L
Crome
S J
SJ
Edlin
A
A
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*; D000818:Animals; D005260:Female; D015497:HIV-1 / Q000145:classification / Q000276:immunology*; D007630:Kenya; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016133:Polymerase Chain Reaction; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology
D016915:AIDS Vaccines; D019444:Vaccines, DNA